Fig 1. A randomized study in patients with relapsed or refractory, CD22-positive, Philadelphia chromosome–positive or Philadelphia chromosome–negative acute lymphoblastic leukemia: inotuzumab ...
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results